Yantai Zhenghai Biotechnology Co., Ltd.

XSEC:300653 Stock Report

Market Cap: CN¥3.8b

Yantai Zhenghai Biotechnology Past Earnings Performance

Past criteria checks 3/6

Yantai Zhenghai Biotechnology has been growing earnings at an average annual rate of 11.6%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 8.9% per year. Yantai Zhenghai Biotechnology's return on equity is 18.7%, and it has net margins of 43.8%.

Key information

11.6%

Earnings growth rate

13.6%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate8.9%
Return on equity18.7%
Net Margin43.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Yantai Zhenghai Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSEC:300653 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2438316812639
30 Jun 2438716712741
31 Mar 2439417812840
31 Dec 2341419113244
30 Sep 2341417814044
30 Jun 2342619114044
31 Mar 2342518414142
01 Jan 2343318514638
30 Sep 2244019715039
30 Jun 2243119214738
31 Mar 2241618014936
31 Dec 2140016915235
30 Sep 2137814915732
30 Jun 2136014414830
31 Mar 2135114314429
31 Dec 2029311812627
30 Sep 2029512312224
30 Jun 2028211112622
31 Mar 2026310012622
31 Dec 1928010713121
30 Sep 1925110011919
30 Jun 192439711418
31 Mar 192309110718
31 Dec 182168610017
30 Sep 18216889617
30 Jun 18204818725
31 Mar 18193768819
31 Dec 17183629516
30 Sep 171765410012
30 Jun 17164471060
31 Mar 17159461020
31 Dec 1615145950
30 Jun 1613843890
31 Mar 1612641810
31 Dec 1512842800
31 Dec 1410534650
31 Dec 137716520

Quality Earnings: 300653 has high quality earnings.

Growing Profit Margin: 300653's current net profit margins (43.8%) are higher than last year (43.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300653's earnings have grown by 11.6% per year over the past 5 years.

Accelerating Growth: 300653's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 300653 had negative earnings growth (-6%) over the past year, making it difficult to compare to the Biotechs industry average (0.08%).


Return on Equity

High ROE: 300653's Return on Equity (18.7%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies